Camrelizumab clinical trials
Also written SHR-1210 and Carrelizumab.
How each study uses camrelizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the camrelizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- Carrelizumab
- 4
In one entry with another drug
Given together, or one or the other
Studies by the year they started
393 studies that test it; most in 2021 (87)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 12 |
| 2018 | 29 |
| 2019 | 39 |
| 2020 | 83 |
| 2021 | 87 |
| 2022 | 47 |
| 2023 | 25 |
| 2024 | 25 |
| 2025 | 20 |
| 2026 | 20 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 51 · Other 342
Jiangsu HengRui Medicine Co., Ltd. (44) · Fudan University (29) · Sun Yat-sen University (28) · Henan Cancer Hospital (14) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (14) · Tianjin Medical University Cancer Institute and Hospital (13) · Peking Union Medical College Hospital (9) · The First Affiliated Hospital of Zhengzhou University (9)
Often tested with
Tested in the same studies.
Apatinib (111) · Famitinib (17) · Fluzoparib (14) · Paclitaxel (13) · Albumin-Bound Paclitaxel (9) · Lenvatinib (6) · Dalpiciclib (6) · Pyrotinib (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Camrelizumab is the comparator. A study of two new drugs counts under both.
- 1Iparomlimab/Tuvonralimab · Qilu Pharmaceutical Co., Ltd.
- 1Thalidomide · Shanghai Zhongshan Hospital · next primary completion Jun 2030
- 1Capecitabine · Shanghai Zhongshan Hospital · next primary completion Jun 2030
- 1Adebrelimab · Shanghai Shengdi Pharmaceutical Co., Ltd · next primary completion Oct 2028
- 1Anti-CTLA-4 Monoclonal Antibody SHR-8068 · Shanghai Shengdi Pharmaceutical Co., Ltd · next primary completion Oct 2028
Reaching primary completion within a year · 19, 3 in phase 3
Studies that test camrelizumab, phase 3 first.
- Dec 2026Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerPhase 2/3 · Ruijin Hospital
- Dec 2026Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCPhase 2/3 · Guangxi Medical University
- May 2027Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)Phase 3 · Wen Tianfu
- Dec 2026Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast CancerPhase 2 · Blokhin's Russian Cancer Research Center
- Dec 2026Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaPhase 2 · Ning Jiang, M.D./Ph.D.
- Dec 2026A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Dec 2026Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast CancerPhase 1/2 · Harbin Medical University
- Dec 2026Chemo-immunotherapy for Cervical Cancer Stage IIICp TrialPhase 2 · Women's Hospital School Of Medicine Zhejiang University
- Dec 2026Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentPhase 2 · Sun Yat-sen University
- Dec 2026Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerPhase 1 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studies
Open first, then newest update. How each study uses camrelizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 393
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingPhase 3Fudan UniversityNCT05999149Written as Camrelizumab Plus Chemotherapy and Famitinib
- A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCRecruitingPhase 2/3Guangzhou Virotech Pharmaceutical Co., Ltd.NCT07589244Written as VRT106 in combination with camrelizumab and apatinib
- Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later TreatmentRecruitingPhase 2Renmin Hospital of Wuhan UniversityNCT07896096Written as Camrelizumab
- Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCRecruitingPhase 2/3Guangxi Medical UniversityNCT05062837Written as Hepatectomy Combined With Camrelizumab and Apatinib
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07505186Written as Camrelizumab
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06423170Written as Camrelizumab plus GEMOX
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Sintilimab+camrelizumab+tislelizumab
- Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Hefei Cancer Hospital of the Chinese Academy of SciencesNCT07787273Written as Camrelizumab
- Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial CancerRecruitingPhase 2Women's Hospital School Of Medicine Zhejiang UniversityNCT06561308Written as Camrelizumab
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingPhase 2Peking University People's HospitalNCT05576389Written as Camrelizumab+Fluzoparib
- Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)RecruitingPhase 2/3Shanghai Zhongshan HospitalNCT06796803Written as camrelizumab combined with rivoceranib and HAIC
- Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT06435260Written as Camrelizumab+chemotherapy
- Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingPhase 1/2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07662681Written as camrelizumab with famitinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Camrelizumab + Apatinib
- Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial CarcinomaNot yet recruitingPhase 2Sheng TaiNCT07639983Written as Trastuzumab Rezetecan plus Camrelizumab
- Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingPhase 2Hunan Cancer HospitalNCT07627620Written as Camrelizumab
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNot applicableHenan Cancer HospitalNCT07618546Written as Camrelizumab (anti-PD-1 inhibitor)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Camrelizumab
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06889688Written as Camrelizumab+Apatinib+Eribulin
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingPhase 2Fudan UniversityNCT07328009Written as TUDCA + Camrelizumab+TKI
See all 393 studies that test camrelizumab →
Given beside what is tested · 47 — camrelizumab is usual care or a partner of the new treatment
- Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07902713Written as Camrelizumab
- Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06992336Written as Apatinib, Camrelizumab
- PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05772273Written as Camrelizumab
- Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital of Henan University of Science and TechnologyNCT07622797Written as Camrelizumab (anti-PD-1 inhibitor)
- Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal CarcinomaRecruitingPhase 3Sun Yat-sen UniversityNCT04944914Written as camrelizumab
- Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07555860Written as Camrelizumab
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationPhase 2Peking UniversityNCT07312578Written as camrelizumab
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingPhase 2Peking Union Medical College HospitalNCT07157969Written as Camrelizumab
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07159217Written as Camrelizumab
- Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic CancerNot yet recruitingPhase 2Fudan UniversityNCT06196671Written as Camrelizumab
- Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaRecruitingPhase 2West China HospitalNCT06831175Written as Camrelizumab
- A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06632405Written as Camrelizumab
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05613478Written as Camrelizumab
- JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingPhase 2Fudan UniversityNCT06731153Written as Camrelizumab (SHR-1210)
- Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabRecruitingPhase 2Fudan UniversityNCT06516289Written as Camrelizumab
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Camrelizumab
- Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06413992Written as Camrelizumab
- The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPCRecruitingPhase 2Chongqing University Cancer HospitalNCT04830267Written as Camrelizumab
- Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic CancerRecruitingEarly Phase 1Jinling Hospital, ChinaNCT06326736Written as Camrelizumab
- Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingPhase 3Fudan UniversityNCT05760378Written as Camrelizumab
Showing 20 of 47.
As the comparator · 5 — what is tested is compared with camrelizumab
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2/3Shanghai Zhongshan HospitalNCT07309419Written as Camrelizumab
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCRecruitingPhase 3Linhui PengNCT07267806Written as Camrelizumab and apatinib
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingPhase 2/3Shanghai Shengdi Pharmaceutical Co., LtdNCT06335355Written as Camrelizumab + Pemetrexed + Carboplatin
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT05367687Written as Camrelizumab
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal CarcinomaActive, not recruitingPhase 2/3Qilu Pharmaceutical Co., Ltd.NCT05576272Written as Carrelizumab
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
Codes
What other systems call camrelizumab · ClinicalTrials.gg INT001114
- MeSH (NLM) C000631724camrelizumabOne source NLM
- UNII (FDA) 73096E137ECAMRELIZUMABConfirmed FDA, NLM
- NCI Thesaurus C123816CamrelizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631724 | camrelizumab | One source NLM |
| UNII (FDA) | 73096E137E | CAMRELIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C123816 | Camrelizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.